Weidemann Frank, Niemann Markus, Breunig Frank, Herrmann Sebastian, Beer Meinrad, Störk Stefan, Voelker Wolfram, Ertl Georg, Wanner Christoph, Strotmann Jörg
Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Josef-Schneider Str 2, Bau 4, 97080 Würzburg, Germany.
Circulation. 2009 Feb 3;119(4):524-9. doi: 10.1161/CIRCULATIONAHA.108.794529. Epub 2009 Jan 19.
Enzyme replacement therapy with recombinant alpha-galactosidase A reduces left ventricular hypertrophy and improves regional myocardial function in patients with Fabry disease during short-term treatment. Whether enzyme replacement therapy is effective in all stages of Fabry cardiomyopathy during long-term follow-up is unknown.
We studied 32 Fabry patients over a period of 3 years regarding disease progression and clinical outcome under enzyme replacement therapy. Regional myocardial fibrosis was assessed by magnetic resonance imaging late-enhancement technique. Echocardiographic myocardial mass was calculated with the Devereux formula, and myocardial function was quantified by ultrasonic strain-rate imaging. In addition, exercise capacity was measured by bicycle stress test. All measurements were repeated at yearly intervals. At baseline, 9 patients demonstrated at least 2 fibrotic left ventricular segments (severe myocardial fibrosis), 11 had 1 left ventricular segment affected (mild fibrosis), and 12 were without fibrosis. In patients without fibrosis, enzyme replacement therapy resulted in a significant reduction in left ventricular mass (238+/-42 g at baseline, 202+/-46 g at 3 years; P for trend <0.001), an improvement in myocardial function (systolic radial strain rate, 2.3+/-0.4 and 2.9+/-0.6 seconds(-1), respectively; P for trend=0.045), and a higher exercise capacity obtained by bicycle stress exercise (106+/-14 and 122+/-26 W, respectively; P for trend=0.014). In contrast, patients with mild or severe fibrosis showed a minor reduction in left ventricular hypertrophy and no improvement in myocardial function or exercise capacity.
These data suggest that treatment of Fabry cardiomyopathy with recombinant alpha-galactosidase A should best be started before myocardial fibrosis has developed to achieve long-term improvement in myocardial morphology and function and exercise capacity.
重组α-半乳糖苷酶A的酶替代疗法在短期治疗期间可减轻法布里病患者的左心室肥厚并改善局部心肌功能。长期随访中法布里心肌病各阶段酶替代疗法是否有效尚不清楚。
我们对32例法布里病患者进行了为期3年的研究,观察酶替代疗法下的疾病进展和临床结局。采用磁共振成像延迟强化技术评估局部心肌纤维化。用德弗罗公式计算超声心动图心肌质量,并用超声应变率成像对心肌功能进行量化。此外,通过自行车运动试验测量运动能力。所有测量每年重复一次。基线时,9例患者至少有2个左心室节段出现纤维化(严重心肌纤维化),11例有1个左心室节段受累(轻度纤维化),12例无纤维化。在无纤维化的患者中,酶替代疗法使左心室质量显著降低(基线时为238±42 g,3年时为202±46 g;趋势P<0.001),心肌功能改善(收缩期径向应变率分别为2.3±0.4和2.9±0.6秒-1;趋势P=0.045),通过自行车运动试验获得的运动能力更高(分别为106±14和122±26 W;趋势P=0.014)。相比之下,轻度或重度纤维化患者的左心室肥厚仅略有减轻,心肌功能或运动能力未改善。
这些数据表明,用重组α-半乳糖苷酶A治疗法布里心肌病最好在心肌纤维化出现之前开始,以实现心肌形态、功能和运动能力的长期改善。